Metastatic Breast Cancer — Current and Future Integration of Antibody-Drug Conjugates
Episode 137 •
20th October 2025 • Oncology Today with Dr Neil Love • Dr. Neil Love
00:00:00
00:56:45
More Episodes
136.
Lung Cancer — 5-Minute Journal Club Issue 3 with Dr Aaron Lisberg: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
135.
Non-Hodgkin Lymphoma — The Implications of Recent Datasets for Current and Future Disease Management
134.
HR-Positive and Triple-Negative Metastatic Breast Cancer — An Interview with Dr Laura Huppert on Optimal Integration of ADCs into Treatment
133.
Follicular Lymphoma — Proceedings from a Session Held During the Society of Hematologic Oncology 2025 Annual Meeting
130.
Relapsed/Refractory Multiple Myeloma — Proceedings from a Session Held During the Society of Hematologic Oncology 2025 Annual Meeting
129.
Breast Cancer — 5-Minute Journal Club Issue 3 with Dr Kevin Kalinsky: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
128.
Metastatic BRCA-Negative, Triple-Negative Breast Cancer — An Interview with Prof Peter Schmid on Optimal Management
127.
Extrapulmonary Neuroendocrine Carcinoma — An Interview with Dr Jonathan Strosberg on Current and Future Management
126.
Oncology Nursing Update: Multiple Myeloma — An Interview with Dr Beth Faiman on CAR T-Cell Therapy
124.
Ocular Toxicities Associated with Antibody-Drug Conjugates and Other Cancer Therapies: Part 2 — An Interview with Dr Neel Pasricha on Adverse Event Management
123.
Ocular Toxicities Associated with Antibody-Drug Conjugates and Other Cancer Therapies: Part 1 — Inside the Issue of Adverse Event Management
122.
Non-Small Cell Lung Cancer — 5-Minute Journal Club Issue 2 with Dr Jacob Sands: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
121.
Metastatic Breast Cancer — Optimizing the Use of Oral Selective Estrogen Receptor Degraders: Part 1
120.
Oncology Nursing Update: Newly Diagnosed Multiple Myeloma — An Interview with Ms Charise Gleason
119.
Oncology Nursing Update: Newly Diagnosed Multiple Myeloma — An Interview with Prof Xavier Leleu
118.
Breast Cancer — 5-Minute Journal Club Issue 2 with Dr Erika Hamilton: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
117.
Relapsed/Refractory Multiple Myeloma — Oncology Q&A: Discussing Common Questions Posed by Patients
115.
Brain Metastases with HER2-Positive Breast Cancer — An Interview with Dr Sarah Sammons on Optimal Management Approaches
113.
Ovarian and Endometrial Cancer — An Interview with Dr Shannon Westin on the Current Management Paradigm
112.
Non-Small Cell Lung Cancer — 5-Minute Journal Club Issue 1 with Dr Jacob Sands: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
111.
Multiple Myeloma | Oncology Q&A — Patient Education Resource: Clinical Experts Address Common Questions Posed by Patients with Relapsed/Refractory Multiple Myeloma
110.
Acute Myeloid Leukemia — An Interview with Dr Jorge Cortes on Optimal Management of FLT3 and IDH1/2 Mutations
107.
Breast Cancer — 5-Minute Journal Club Issue 1 with Dr Erika Hamilton: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
105.
Oncology Nursing Update: Prostate Cancer — An Interview with Ms Kathleen D Burns on the Current Treatment Paradigm and New Approaches to Patient Care
104.
Endocrine-Resistant HR-Positive Metastatic Breast Cancer — An Interview with Dr Hope S Rugo on Optimal Management
103.
Soft Tissue Sarcoma and Other Connective Tissue Neoplasms — Proceedings from a Webinar Held in Conjunction with the 2025 ASCO Annual Meeting
102.
Renal Cell Carcinoma — Proceedings from a Webinar Held in Conjunction with the 2025 ASCO Annual Meeting
101.
Chronic Lymphocytic Leukemia — Proceedings from a Session Held During the 2025 ASCO Annual Meeting
100.
Oncology Nursing Update: Ovarian Cancer — An Interview with Ms Jennifer Filipi on the Current Treatment Paradigm and New Approaches
99.
Multiple Myeloma — Proceedings from a Webinar Held in Conjunction with the 2025 ASCO Annual Meeting
98.
Lung Cancer — Proceedings from a Session Held During the 2025 ASCO Annual Meeting on the Current and Future Role of Immunotherapy and Antibody-Drug Conjugates
96.
HER2-Positive Gastrointestinal Cancers — Proceedings from a Session Held During the 2025 ASCO Annual Meeting
95.
For Oncology Nurses: Chronic Lymphocytic Leukemia — Proceedings from the 2025 Annual ONS Congress
92.
For Oncology Nurses: DLL3-Targeting Bispecific T-Cell Engagers for Small Cell Lung Cancer — Proceedings from the 2025 Annual ONS Congress
88.
Ovarian and Endometrial Cancer — Proceedings from a Session Held During the 2025 ASCO Annual Meeting
84.
IDH-Mutant Low-Grade Glioma — An Interview with Dr Patrick Y Wen on Current and Future Management Strategies
83.
EGFR Mutation-Positive Non-Small Cell Lung Cancer — Proceedings from a Session Held During the 2025 ASCO Annual Meeting
80.
For Oncology Nurses: Hormone Receptor-Positive Breast Cancer — Proceedings from the 2025 Annual ONS Congress
77.
Non-Small Cell Lung Cancer and Therapeutic Targets Beyond EGFR — Year in Review Series on Relevant New Datasets and Advances
74.
Breast Cancer: Additional Perspectives — Year in Review Series on Relevant New Datasets and Advances
73.
Prostate Cancer and AKT Inhibitors — Proceedings from a Session Held During the American Urological Association Annual Meeting
72.
Systemic Mastocytosis and Myelofibrosis — Fourth Annual National General Medical Oncology Summit
68.
Multiple Myeloma — An Interview with Dr Rafael Fonseca on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting
67.
5-Minute Journal Club Issue 8 with Dr Rinath M Jesselsohn: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer
65.
Chronic Lymphocytic Leukemia — An Interview with Dr Lindsey Roeker on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting
64.
Relapsed/Refractory Follicular Lymphoma Part 3 — A Roundtable Discussion on the Selection and Sequencing of Other Novel Therapies
61.
Non-Hodgkin Lymphoma — An Interview with Dr Jennifer Crombie on the Use of Bispecific Antibodies
60.
5-Minute Journal Club Issue 7 with Dr Rinath M Jesselsohn: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer
59.
Immunotherapy and Nontargeted Approaches for NSCLC — Fourth Annual National General Medical Oncology Summit
57.
Relapsed/Refractory Follicular Lymphoma Part 2 — A Roundtable Discussion on the Selection and Sequencing of CAR T-Cell Therapy
53.
Non-Hodgkin Lymphoma — An Interview with Dr John P Leonard on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting
46.
For Oncology Nurses: Antibody-Drug Conjugates for Breast Cancer and Lung Cancer — Proceedings from the 2025 Annual ONS Congress
45.
Hormone Receptor-Positive Metastatic Breast Cancer — An Interview with Dr Adam M Brufsky on the Impact of Biomarkers and Existing Comorbidities on the Selection of First-Line Therapy
43.
Relapsed/Refractory Follicular Lymphoma Part 1 — A Roundtable Discussion on the Selection and Sequencing of Bispecific Antibodies
42.
HER2-Positive and Triple-Negative Breast Cancer — Fourth Annual National General Medical Oncology Summit
40.
Ovarian Cancer — Proceedings from a Session Held During the 2025 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer®️
39.
Myelofibrosis — An Interview with Dr Raajit K Rampal on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting
38.
Sarcoma and Other Connective Tissue Neoplasms — Fourth Annual National General Medical Oncology Summit
34.
First-Line Therapy for Metastatic Non-Small Cell Lung Cancer and an ALK Rearrangement — An Interview with Dr Justin F Gainor
32.
Chronic Lymphocytic Leukemia — An Interview with Dr Catherine C Coombs on Real-World Cases and Current Questions and Controversies Presented at Recent Conferences
31.
HER2-Positive Gynecologic Cancers — Proceedings from a Session Held During the 2025 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer®️
30.
HR-Positive Breast Cancer — An Interview with Dr Sara A Hurvitz on the Role of Endocrine-Based Therapy
29.
For Oncology Nurses: Bispecific Antibodies in Multiple Myeloma — An Interview with Dr Tiffany A Richards
28.
5-Minute Journal Club Issue 6 with Dr Komal Jhaveri: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer
25.
Renal Cell Carcinoma — Proceedings from a Session Held in Conjunction with the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU)
23.
Localized Breast Cancer — Examining the Current Use of Genetic Testing and Related Clinical Management
22.
Urothelial Bladder Cancer and Prostate Cancer — Proceedings from a Session Held in Conjunction with the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU)
21.
5-Minute Journal Club Issue 5 with Dr Komal Jhaveri: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer
19.
Relapsed/Refractory Diffuse Large B-Cell Lymphoma — A Roundtable Discussion on Current and Future Management Strategies
18.
Colorectal Cancer — Proceedings from a Session Held in Conjunction with the 2025 ASCO Gastrointestinal Cancers Symposium (ASCO GI)
17.
Multiple Myeloma — An Interview with Dr Surbhi Sidana on Optimizing the Role of CAR T-Cell Therapy
16.
HER2-Low and HER2-Ultralow Breast Cancer — A Roundtable Discussion on Current and Future Management Strategies
15.
Hepatocellular Carcinoma — Proceedings From a Session Held in Conjunction with the 2025 ASCO Gastrointestinal Cancers Symposium (ASCO GI)
14.
5-Minute Journal Club Issue 4 with Dr Seth Wander: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer
13.
EGFR-Mutant Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances
11.
5-Minute Journal Club Issue 3 with Dr Seth Wander: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer
10.
Chronic Lymphocytic Leukemia with Dr Jennifer Woyach: Part 3 of a 3-Part Meet The Professor Series
9.
Metastatic Triple-Negative Breast Cancer — Oncology Q&A for Clinicians: Discussing Common Questions Posed by Patients
8.
Data + Perspectives: Clinical Investigators Discuss the Role of CAR T-Cell Therapy for Patients with Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
6.
CAR T-Cell and Bispecific Therapy for Lymphoma — Part 3 of Our 6-Part ASH 2024 Friday Satellite Symposia Series
1.
The Role of Endocrine-Based Therapy in the Management of Breast Cancer — San Antonio 2024 symposium series proceedings Part 2
Cases from the Community: Integrating New Research Findings into Current Practice — Colorectal and Gastroesophageal Cancers
Cases from the Community: Integrating New Research Findings into Current Practice — Hepatobiliary Cancers
Cases from the Community: Integrating New Research Findings into Current Practice — Gynecologic Cancers
Cases from the Community: Integrating New Research Findings into Current Practice — Leukemia and Myelodysplastic Syndromes
5-Minute Journal Club Issue 2 with Dr Seth Wander: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer
Meet The Professor: Current and Future Use of Nontargeted Therapy for Metastatic Non-Small Cell Lung Cancer — A 2024 World Conference on Lung Cancer Review
Exploring the Current Management Paradigm for Patients with Metastatic Triple-Negative Breast Cancer
Practical Perspectives: Investigators Discuss the Current Management of Paroxysmal Nocturnal Hemoglobinuria
Data + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology Care — Multiple Myeloma
5-Minute Journal Club Issue 1 with Dr Seth Wander: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer
The Implications of Recent Datasets for the Current and Future Management of Lung Cancer — A Review of Information from ESMO Congress 2024 and Other Conferences
Meet The Professor: Optimizing the Management of Chronic Lymphocytic Leukemia — Part 2 of a 3-Part Series
Data + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology Care — Prostate Cancer
Data + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology Care — Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Optimizing Therapy for Patients with Hormone Receptor-Positive Metastatic Breast Cancer Harboring PI3K/AKT/PTEN Pathway Abnormalities
Data + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology Care — Lung Cancer
Data + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology Care — Breast Cancer
What Clinicians Want to Know About the Current and Future Role of EZH1/2 Inhibitors in the Care of Patients with Lymphoma
The Implications of Recent Datasets for the Current and Future Management of Gastrointestinal Cancers — An ESMO Congress 2024 Review
Improving Outcomes with First-Line Endocrine-Based Therapy for Patients with HR-Positive, HER2-Negative Metastatic Breast Cancer
Practical Perspectives: Optimizing the Role of BTK Inhibitors in the Management of Mantle Cell Lymphoma
The Implications of Recent Datasets for the Current and Future Management of Small Cell Lung Cancer — A 2024 World Conference on Lung Cancer Review
The Implications of Recent Datasets for the Current and Future Use of Nontargeted Therapy for Metastatic Non-Small Cell Lung Cancer
Meet The Professor: Optimizing the Management of Chronic Lymphocytic Leukemia — Part 1 of a 3-Part Series
The Implications of Recent Datasets for the Current and Future Management of Non-Small Cell Lung Cancer with Actionable Targets Beyond EGFR
The Implications of Recent Datasets for the Current and Future Management of Non-Small Cell Lung Cancer with EGFR Mutations
Inside the Issue: Integrating HER2-Targeted Strategies into the Management of Gastrointestinal Cancers
Inside the Issue: Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metastatic Breast Cancer
Special Edition — Key Presentations on Breast Cancer from the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Inside the Issue: Integrating ALK-Targeted Therapy into the Management of Localized Non-Small Cell Lung Cancer
Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metastatic Breast Cancer
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Multiple Myeloma
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Melanoma and Nonmelanoma Skin Cancers
Individualizing the Selection of First-Line Therapy for Patients with Hormone Receptor-Positive Metastatic Breast Cancer
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Immunotherapy and Other Nontargeted Approaches for Lung Cancer
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Gynecologic Oncology
An interview with Jonathan W Goldman, MD — Management of Non-Small Cell Lung Cancer with an EGFR Mutation
Investigator Perspectives on Available Research and Challenging Questions in Melanoma and Nonmelanoma Skin Cancers: A Post-ASCO 2024 Annual Review
Investigator Perspectives on Available Research and Challenging Questions in Renal Cell Carcinoma: A Post-ASCO Annual Review
RTP Live from Chicago: Investigator Perspectives on Recent Advances and Challenging Questions in the Management of Colorectal Cancer
RTP Live from Chicago: Investigator Perspectives on the Role of Bispecific Antibodies in the Management of Lymphoma
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Myelofibrosis
Striving for Consensus: Exploring the Current Role of Ovarian Suppression in the Management of Breast Cancer
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Targeted Therapy for Non-Small Cell Lung Cancer
Second Opinion: Urologic Oncology Investigators Discuss How They Apply Clinical Research in the Care of Patients with Urothelial Bladder Cancer
Understanding the Risk of Recurrence and Related Management for Patients with Localized HER2-Positive Breast Cancer
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Acute Myeloid Leukemia
Role of HER2-Directed Therapy in the Treatment of HER2-Expressing Urothelial Bladder Cancer — Part 3 of a Special 3-Part Edition
Special Edition – Prostate Cancer Updates from a CME Program Held at the 2024 Genitourinary Cancers Symposium
Role of HER2-Directed Therapy in the Treatment of HER2-Expressing Gastrointestinal Cancers — Part 2 of a Special 3-Part Edition
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Colorectal Cancer
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Urothelial Bladder Cancer
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Prostate Cancer
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Lymphoma
Consensus or Controversy? Immune Checkpoint Inhibitors in the Management of Hepatobiliary Cancers — A 2024 Post-ASCO Gastrointestinal Cancers Symposium Review
Promising Therapeutic Strategies for Patients with Progressive Metastatic Non-Small Cell Lung Cancer
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in HER2-Positive and Triple-Negative Breast Cancer
Understanding the Current and Future Role of Oral SERDs (Selective Estrogen Receptor Degraders) in the Management of ER-Positive Metastatic Breast Cancer
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Gastroesophageal Cancers
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Chronic Lymphocytic Leukemia
Consensus or Controversy? Investigator Perspectives on the Current and Future Role of Immune Checkpoint Inhibitors in the Management of Hepatobiliary Cancers
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Hormone Receptor-Positive Breast Cancer
Meet The Professor: Optimizing the Management of Acute Myeloid Leukemia and Myelodysplastic Syndromes — Part 3 of a 3-Part Series
Role of HER2-Directed Therapy in the Treatment of HER2-Expressing Gynecologic Cancers — Part 1 of a Special 3-Part Edition
Meet The Professor: Optimizing the Management of Gastroesophageal Cancers — Part 3 of a 3-Part Series
Meet The Professor: Optimizing the Management of Gastroesophageal Cancers — Part 2 of a 3-Part Series
Meet The Professor: Optimizing the Management of Acute Myeloid Leukemia and Myelodysplastic Syndromes — Part 2 of a 3-Part Series
Meet The Professor: Optimizing the Management of Gastroesophageal Cancers — Part 1 of a 3-Part Series
Meet The Professor: Optimizing the Management of Acute Myeloid Leukemia and Myelodysplastic Syndromes — Part 1 of a 3-Part Series
Inside the Issue: Integrating Targeted and Immunotherapy into the Management of Localized Non-Small Cell Lung Cancer
Practical Perspectives: Investigators Discuss Current Management and Actual Cases of Relapsed/Refractory Metastatic Colorectal Cancer
Inside the Issue: Optimizing the Management of Metastatic BRCA-Negative, Triple-Negative Breast Cancer
Emerging Role of CELMoDs (Cereblon E3 Ligase Modulators) and Other Novel Approaches to Targeting Protein Degradation Pathways in Multiple Myeloma
The Current and Future Role of CD20 x CD3 Bispecific Antibodies in the Management of Non-Hodgkin Lymphoma
Striving for Consensus: Current and Future Management of Metastatic Non-Small Cell Lung Cancer in Patients Who Experience Disease Progression on Immune Checkpoint Inhibitor Therapy
Exploring the Current and Future Management of High-Risk, Hormone-Sensitive Nonmetastatic Prostate Cancer
Meet The Professor: Optimizing the Management of Soft Tissue Sarcoma and Related Connective Tissue Disorders — Part 2 of a 2-Part Series
Special Edition — Key Presentations on Chronic Lymphocytic Leukemia and Lymphoma from Recent Major Oncology/Hematology Conferences
Special Edition — Key Presentations on Genitourinary Cancers from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Current and Future Management of ER-Positive Metastatic Breast Cancer After Disease Progression on a CDK4/6 Inhibitor
Integrating Bispecific Antibodies into the Management of Multiple Myeloma — Patient Selection and Toxicity Management
Special Edition — Key Presentations on Lung Cancer from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Special Nursing Edition — What I Tell My Patients About New Treatments and Clinical Trials in Chronic Lymphocytic Leukemia
Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Melanoma and Nonmelanoma Skin Cancers
Special Edition — Key Presentations from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Gastrointestinal Cancers Issue
Special Edition — Key Presentations on Gynecologic Cancers from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Ready for Prime Time? Determining the Current and Future Role of PARP Inhibitor-Based Combinations in the Management of Prostate Cancer — A Clinical Investigator Think Tank
Special Edition — Key Presentations from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Ovarian Cancer Issue
Special Nursing Edition — What I Tell My Patients About New Treatments and Clinical Trials in Colorectal and Gastroesophageal Cancers
Special Nursing Edition — What I Tell My Patients About New Treatments and Clinical Trials in Urothelial Bladder Cancer
Meet The Professor: Optimizing the Management of Soft Tissue Sarcoma and Related Connective Tissue Disorders — Part 1 of a 2 - Part Series
Key Presentations from the 64th American Society of Hematology (ASH) Annual Meeting: Multiple Myeloma Edition
Key Presentations from the 64th American Society of Hematology (ASH) Annual Meeting: Chronic Lymphocytic Leukemia Edition
Key Presentations in Hodgkin and Non-Hodgkin Lymphomas from the 2022 ASH Annual Meeting with Dr Matthew Lunning
Key Presentations on Myeloproliferative Neoplasms from the 2022 ASH Annual Meeting — With Dr Srdan Verstovsek
Key Presentations in Acute Myeloid Leukemia and Myelodysplastic Syndromes from the 2022 ASH Annual Meeting with Dr Richard Stone